-
Sichuan Biokin Pharma Plans IPO on STAR Board to Raise RMB 1.422 Billion
•
China-based Sichuan Biokin Pharmaceutical Co., Ltd is set to conduct an initial public offering (IPO) of 40.1 million shares on the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR). The offering is expected to raise a total of RMB 1.422 billion (USD 196.6 million). The proceeds will be allocated towards the…
-
Mabwell Bioscience’s 9MW3011 Accepted for Review by China’s NMPA
•
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that its clinical filing for the Category 1 drug candidate 9MW3011 in β-Thalassemia and polycythemia vera has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant step forward in the development of innovative treatments…
-
Zhiyi Biotechnology Receives FDA Clearance for SK10 in Chemotherapy-Induced Diarrhea
•
Guangzhou-based Zhiyi Biotechnology has announced receiving clearance from the US FDA for a clinical study of its SK10 (inactivated Bacteroides fragilis) in chemotherapy-induced diarrhea (CID). This marks a significant milestone in the development of live biotherapeutic products (LBPs) for addressing unmet medical needs. First-in-Class IND ApprovalNotably, this is the world’s…
-
Shanghai’s Hrain Biotechnology Plans IPO on STAR Board to Raise RMB 2.539 Billion
•
Shanghai-based Hrain Biotechnology Co., Ltd, a specialist in tumor immunotherapy, plans to conduct an initial public offering (IPO) of 50 million shares on the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR). The offering is expected to raise RMB 2.539 billion (USD 352.6 million). The proceeds will be allocated towards cell…
-
Sirnaomics Initiates Phase I Study of STP705 for Abdominal Fat Reduction
•
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has announced the first subject dosing in a Phase I clinical study for its STP705, targeting adult abdominal fat reduction. The study, expected to report results during the first half of 2023, marks a significant step forward in the development of non-invasive…
-
Gritgen Therapeutics Secures Hundreds of Millions in A-Round Financing for Gene Therapy Pipeline
•
Gritgen Therapeutics, a leading gene therapy drug developer based in Suzhou, has announced the successful completion of a A-round financing round worth several hundred million yuan. The financing was led by Sequoia China, with participation from Sunlight Insurance, Qingsong Capital, and Beijing Life Science Park Venture Fund. Existing shareholders including…
-
Shenzhen-Based Pregbio Raises Funds for Non-Invasive Prenatal Gene Detection
•
Pregbio, a Shenzhen-based non-invasive prenatal gene detection company, has reportedly raised an undisclosed amount of money in an angel financing round. The sole contributor to the round was ASB Ventures. The proceeds will be used to promote early screening and diagnosis of preterm labor and pre-eclampsia, non-invasive prenatal screening, and…
-
Novartis Cuts Back on US Development of BeiGene’s PD-1 Inhibitor Tislelizumab
•
Novartis AG (NYSE: NVS), BeiGene’s partner, revealed in its Q3 2022 earnings report that it is scaling back the US development of the programmed death-1 (PD-1) inhibitor tislelizumab. The firm no longer plans to file a New Drug Application (NDA) in the US for nasopharyngeal carcinoma (NPC) and has ended…
